Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | PPARG | P37231 | 9/20 | 0.45 |
| ▸ | PPARA | Q07869 | 8/20 | 0.45 |
| ▸ | PPARD | Q03181 | 6/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | MMP1 | P03956 | 1/20 | 0.38 |
| ▸ | MMP9 | P14780 | 1/20 | 0.38 |
| ▸ | MMP13 | P45452 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6387462 | 1.00 | LMNA (0.47) | LMNAALDH1A1PPARGPPARAPPARD | |
| SCHEMBL6396442 | 0.88 | PPARA (0.48) | LMNAALDH1A1PPARGPPARAPPARD | |
| SCHEMBL7755910 | 0.85 | PPARG (0.61) | LMNAALDH1A1PPARGPPARAPPARD | |
| SCHEMBL16456500 | 0.82 | PPARA (0.44) | LMNAALDH1A1PPARGPPARAPPARD | |
| SCHEMBL16456491 | 0.82 | PPARG (0.44) | LMNAALDH1A1PPARGPPARAPPARD | |
| SCHEMBL5365650 | 0.81 | PPARA (0.58) | LMNAALDH1A1PPARGPPARAPPARD | |
| SCHEMBL4451916 | 0.80 | PPARA (0.46) | LMNAALDH1A1PPARGPPARAPPARD | |
| SCHEMBL3963055 | 0.79 | BLM (0.50) | LMNAALDH1A1PPARGPPARAPPARD | |
| SCHEMBL5197222 | 0.79 | BLM (0.50) | LMNAALDH1A1PPARGPPARAPPARD | |
| SCHEMBL5365631 | 0.77 | PPARA (0.49) | LMNAALDH1A1PPARGPPARAPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010027198-A1 | Novel heterocyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them | DR. REDDY'S RESEARCH FOUNDATION & REDDY-CHEMINOR INC. | 2001-10-04 | — | — | US | disclosed |
| EP-1124807-A1 | NOVEL HETEROCYCLIC COMPOUNDS AND THEIR USE IN MEDICINE, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DR. REDDY'S RESEARCH FOUNDATION (IN) | 2001-08-22 | — | — | EP | disclosed |
| WO-1999016758-A1 | NOVEL HETEROCYCLIC COMPOUNDS AND THEIR USE IN MEDICINE, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DR. REDDY'S RESEARCH FOUNDATION (IN) | 1999-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010027198-A1 | Novel heterocyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them | CYP11B1, CYP46A1, CYP51A1 | LMNA 1390/4885ALDH1A1 1511/4885PPARG 102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.